

1FW

# Electronic Filing System (EFS) Data

## Electronic Patent Application Submission

~~USPS~~ Use Only



EFS ID: 53936  
Application ID: 10712363  
Title of Invention: Cytochrome P450 genetic variations  
First Named Inventor: Elliott Dawson  
Domestic/Foreign Application: Domestic Application  
Filing Date: 2003-11-12  
Effective Receipt Date: 2004-01-19  
Submission Type: Information Disclosure Statement  
Filing Type:  
Confirmation number: 1313  
Attorney Docket Number: 13744-2



Total Fees Authorized:

Digital Certificate Holder: cn=David A. Farah,ou=Registered Attorneys,ou=Patent and Trademark Office,ou=Department of Commerce,o=U.S. Government,c=US

Certificate Message Digest: 88656fd55e99d41e46609c0d1b27a9af4b8bc355




## TRANSMITTAL

Electronic Version v1.1  
Stylesheet Version v1.1.0

Title of Invention	Cytochrome P450 genetic variations	
Application Number:	10/712363	
Date:	2003-11-12	
First Named Applicant:	Elliott P. Dawson	
Confirmation Number:	1313	
Attorney Docket Number:	13744-2	
<p>I hereby certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.</p> <p>I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.</p>		
Submitted by:	Elec. Sign.	Sign. Capacity
David A. Farah Registered Number: 38134	/davidfarah/	Attorney
Documents being submitted us-ids	Files EfilingIDS13744-2-usidst.xml us-ids.dtd us-ids.xsl	
Comments		
It is believed that this disclosure complies with the requirements of 37 C.F.R. 1.56 and		

the Manual of Patent Examining Procedures Section 707.05 (b). If for some reason the Examiner considers otherwise, it is respectfully requested that the undersigned be called so that any deficiencies can be remedied. Applicant believes that because this Disclosure Statement is being submitted within three months of the filing date and/or before the first Office Action on the merits, no fee is due. If this is incorrect, please charge any necessary fee for consideration of this Disclosure Statement to Deposit Account No. 19-2090 (Sheldon and Mak). No fee is believed due in connection with this communication. However, if it is determined that a fee is due, the Commissioner is hereby authorized to charge payment of any fees to Deposit Account No. 19-2090.



## ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	Cytochrome P450 genetic variations							
Application Number:		10/712363						
Confirmation Number:		1313						
First Named Applicant:		Elliott Dawson						
Attorney Docket Number:		13744-2						
Art Unit:		1637						
Search string:		( 6309823 ).pn.						
<b>US Patent Documents</b>								
Note: Applicant is not required to submit a paper copy of cited US Patent Documents								
init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass	
	1	6309823	2001-10-30	Cronin et al.	B1	435	6	
<b>Signature</b>								
Examiner Name					Date			